Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-15
2008-04-15
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S012200, C514S374000, C548S210000, C548S232000, C548S235000, C548S236000, C530S324000
Reexamination Certificate
active
10872721
ABSTRACT:
A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
REFERENCES:
patent: 4001228 (1977-01-01), Mattalia
patent: 4051250 (1977-09-01), Dahm et al.
patent: 5187188 (1993-02-01), Meanwell
patent: 5218124 (1993-06-01), Failli et al.
patent: 5254576 (1993-10-01), Romine et al.
patent: 5262540 (1993-11-01), Meanwell
patent: 5348969 (1994-09-01), Romine et al.
patent: 5362879 (1994-11-01), Meanwell
patent: 5380854 (1995-01-01), Romine et al.
patent: 5403852 (1995-04-01), Barreau et al.
patent: 5599770 (1997-02-01), Kubota et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 2.1.56.486 (1973-01-01), None
patent: 2.647.676 (1990-07-01), None
patent: 2054936 (1994-04-01), None
patent: 2033184 (1990-06-01), None
patent: WO92/04334 (1992-03-01), None
patent: WO95/17393 (1995-06-01), None
patent: WO/96/35678 (1996-11-01), None
Kletzien et al., J.Cel.Biochem.Suppl., vol. 15, No. 8, p. 70 (XP002209109) (1991).
Melki et al., J. Lipid Res., vol. 34, No. 9, pp. 1527-1534 (XP001094445) (1993).
Baxa, et al. Biochemistry, vol. 28, No. 22, 1989 pp. 8683-8690.
Hotamisligil, G.S. et al, “Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein”, Science, Vo. 274, Nov. 22, 1996, pp. 1377-1379.
Mai, A. et al, “Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series”, J. Med. Chem., 1997, 40, 1447-1454.
Dialog Alert DBDR928, Jan. 2, 1997, Pharmaprojects No. 5149.
Biller Scott A.
Hotamisligil Gokhan
Jacobson Bruce L.
Jamil Haris
Kodukula Krishna
Bristol--Myers Squibb Company
Duncan Laurelee A.
Miano Rosemary M.
Mohamed Abdel A
President & Fellows of Harvard College
LandOfFree
Method for treating atherosclerosis employing an aP2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating atherosclerosis employing an aP2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating atherosclerosis employing an aP2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3913797